Home
Stock Market News
Market Sentiment
Trending Industries
Blogs
Contact us
Eli Lilly Say Most Tirzepatide Users Remained Diabetes-Free at 176 Weeks
Eli Lilly's Phase 3 study of tirzepatide showed sustained weight loss and nearly 99% remaining diabetes-free at 176 weeks.